Compare FRGE & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRGE | PACB |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 615.4M | 715.5M |
| IPO Year | N/A | 2010 |
| Metric | FRGE | PACB |
|---|---|---|
| Price | $44.37 | $1.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $31.00 | $2.08 |
| AVG Volume (30 Days) | 257.5K | ★ 6.3M |
| Earning Date | 11-13-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $92,884,000.00 | ★ $154,584,000.00 |
| Revenue This Year | $33.10 | $4.48 |
| Revenue Next Year | $24.07 | $11.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.40 | N/A |
| 52 Week Low | $6.60 | $0.85 |
| 52 Week High | $44.78 | $2.73 |
| Indicator | FRGE | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 73.04 | 44.21 |
| Support Level | $44.27 | $1.67 |
| Resistance Level | $44.78 | $1.89 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | -0.50 | -0.03 |
| Stochastic Oscillator | 22.77 | 32.69 |
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.